专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1998017686A1 POLYPEPTIDES COMPRISING GAX PROTEIN DOMAINS, INVOLVED IN REPRESSING TRANSCRIPTION AND/OR INTERACTING WITH OTHER PROTEINS, CORRESPONDING NUCLEIC ACIDS AND THEIR USE 审中-公开
标题翻译：包含GAX蛋白质域的多核苷酸，涉及转录和/或与其他蛋白质相互作用，相关核酸及其使用
公开(公告)号：WO1998017686A1
公开(公告)日：1998-04-30
申请号：PCT/FR1997001850
申请日：1997-10-16
申请人： RHONE-POULENC RORER S.A. , BRANELLEC, Didier , FOURNIER, Alain , MAHFOUDI, Abderrahim , MARCIREAU, Christophe
发明人： RHONE-POULENC RORER S.A.
IPC分类号： C07K14/47
CPC分类号： C07K14/4703 , C07K2319/00 , G01N2500/04 , Y10S977/80 , Y10S977/915
摘要： The invention concerns polynucleotides comprising GAX domains, involved in the biological activity of GAX. In particular it may concern domains involved in the interaction of GAX with other molecules or domains responsible for a biological activity. The invention also concerns the chimerical molecules comprising a functional domain of GAX. It further concerns the use of GAX for repressing the expression of genes, and the use of compounds inhibiting the interaction of GAX with certain cell partners for modulating the activity of GAX, It also concerns a method for screening and/or identifying cell partners of GAX.
摘要翻译：本发明涉及涉及GAX的生物学活性的包含GAX结构域的多核苷酸。特别地，它可能涉及参与GAX与负责生物活性的其他分子或结构域的相互作用的结构域。本发明还涉及包含GAX的功能结构域的嵌合分子。它还涉及使用GAX来抑制基因的表达，以及使用抑制GAX与某些细胞伴侣相互作用来调节GAX活性的化合物。它还涉及用于筛选和/或识别GAX的细胞伴侣的方法。

2. 发明申请

WO1998000524A1 METHOD FOR PRODUCING RECOMBINANT ADENOVIRUS 审中-公开
标题翻译：生产重组腺病毒的方法
公开(公告)号：WO1998000524A1
公开(公告)日：1998-01-08
申请号：PCT/FR1997001107
申请日：1997-06-20
申请人： RHONE-POULENC RORER S.A. , BLANCHE, Francis , GUILLAUME, Jean-Marc
发明人： RHONE-POULENC RORER S.A.
IPC分类号： C12N07/02
CPC分类号： C12N7/00 , B01D15/363 , B01D61/145 , B01J41/20 , C12N15/86 , C12N2710/10343 , C12N2710/10351 , G01N30/02
摘要： The invention concerns a method for producing recombinant adenovirus by which viral DNA is introduced in a packaging cell culture and the viruses produced are harvested after liberation in the supernatant. The invention also concerns the viruses produced and their use.
摘要翻译：本发明涉及生产重组腺病毒的方法，通过该方法将病毒DNA引入包装细胞培养物中，并且在上清液中释放后收获产生的病毒。本发明还涉及所产生的病毒及其用途。

3. 发明申请

WO1997036884A1 METHOD FOR PREPARING 2H-NAPHTHO[1,8-cd]ISOTHIAZOLE-1,1-DIOXIDE 审中-公开
标题翻译：制备2H-萘并[1,8-cd]异噻唑-1,1-二氧化物的方法
公开(公告)号：WO1997036884A1
公开(公告)日：1997-10-09
申请号：PCT/FR1997000533
申请日：1997-03-26
申请人： RHONE-POULENC RORER S.A. , GRONDARD, Luc , HENRIET, Daniel
发明人： RHONE-POULENC RORER S.A.
IPC分类号： C07D275/06
CPC分类号： C07D275/06
摘要： A method for preparing colourless 2H-naphtho[1,8-cd]isothiazole-1,1-dioxide or 1,8-naphthosultam with a purity of more than 99 % by 8-amino-1-naphthalenesulphonic acid cyclisation using phosphoryl chloride in the presence of pyridine, wherein (a) 1.5-2 mol of phosphoryl chloride and 0.05-0.3 mol of pyridine are used per mole of 8-amino-1-naphthalenesulphonic acid in a backflow of toluene, (b) the reaction medium is poured onto an aqueous potash or soda solution and the aqueous and toluene phases are separated, (c) the aqueous phase from b is maintained at a pH of 6-8 and a temperature of 55-80 DEG C, then acidified, and the precipitate is separated, and (d) the raw product is treated with activated carbon in an organic solvent then separated.
摘要翻译：通过使用磷酰氯在8-氨基-1-萘磺酸环化中制备纯度大于99％的无色2H-萘并[1,8-cd]异噻唑-1,1-二氧化物或1,8-萘磺酸钠的方法吡啶的存在，其中（a）在甲苯回流中每摩尔8-氨基-1-萘磺酸使用1.5-2摩尔磷酰氯和0.05-0.3摩尔吡啶，（b）将反应介质倒入分离到水溶液或苏打溶液中，并分离水相和甲苯相，（c）b的水相保持在6-8的温度和55-80℃的温度，然后酸化，沉淀物为分离，（d）将原料在有机溶剂中用活性炭处理然后分离。

4. 发明申请

WO1997033975A1 MEDIUM FOR PRESERVING BIOLOGICAL MATERIALS 审中-公开
标题翻译：保存生物材料的介质
公开(公告)号：WO1997033975A1
公开(公告)日：1997-09-18
申请号：PCT/FR1997000385
申请日：1997-03-05
申请人： RHONE-POULENC RORER S.A. , CRESPO, André , SORIA, Henri-Michel
发明人： RHONE-POULENC RORER S.A.
IPC分类号： C12N01/04
CPC分类号： C12N1/04
摘要： A medium for preserving and/or freezing biological materials, including a saline solution, modified fluid gelatin and human serum albumin, is disclosed.
摘要翻译：公开了一种用于保存和/或冷冻生物材料的介质，包括盐水溶液，改性流体明胶和人血清白蛋白。

5. 发明申请

WO1997025327A1 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME 审中-公开
标题翻译： 5H，10H-咪唑并[1,2-a]茚并[1,2-e]吡嗪-4-酮衍生物，其制备方法和含有其的药物
公开(公告)号：WO1997025327A1
公开(公告)日：1997-07-17
申请号：PCT/FR1997000018
申请日：1997-01-06
申请人： RHONE-POULENC RORER S.A. , DAMOUR, Dominique , HARDY, Jean-Claude , MIGNANI, Serge
发明人： RHONE-POULENC RORER S.A.
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： Compounds of formula (I), wherein R is a hydrogen atom or a -COOH or CH2OH radical, R1 is a -CH-R2 radical, R2 is a 3-dimethyl-1H-pyrazole-4-yl, 4-chloro-1-methylimidazole-5-yl or 3-hydroxy-isoxazole-5-yl radical, except for 10-(1,3-dimethyl-1H-pyrazole-4-methylene)-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, isomers thereof, salts thereof, the preparation thereof and drugs containing said compounds, are disclosed. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the alpha -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartate (NMDA) receptor, and specifically ligands for NMDA receptor glycine modulator sites.
摘要翻译：式（I）化合物，其中R是氢原子或-COOH或CH 2 OH基团，R 1是-CH-R 2基团，R 2是3-二甲基-1H-吡唑-4-基，4-氯-1 - 甲基咪唑-5-基或3-羟基 - 异恶唑-5-基，除了10-（1,3-二甲基-1H-吡唑-4-亚甲基）-5H，10H-咪唑并[1,2-a] 茚并[1,2-e]吡嗪-4-酮，其异构体，其盐，其制备方法和含有所述化合物的药物。式（I）化合物具有有价值的药理学性质，也是也称为quisqualate受体的α-氨基-3-羟基-5-甲基-4-异恶唑丙酸（AMPA）受体的拮抗剂。此外，式（I）化合物是N-甲基-D-天冬氨酸（NMDA）受体的非竞争性拮抗剂，特别是NMDA受体甘氨酸调节剂位点的配体。

6. 发明申请

WO1997025326A1 2-SUBSTITUTED 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME 审中-公开
标题翻译： 2-取代的5H，10H-咪唑并[1,2-a]茚并[1,2-e]吡嗪-4-酮，其制备方法和含有其的药物
公开(公告)号：WO1997025326A1
公开(公告)日：1997-07-17
申请号：PCT/FR1997000017
申请日：1997-01-06
申请人： RHONE-POULENC RORER S.A. , ALOUP, Jean-Claude , BOUQUEREL, Jean , DAMOUR, Dominique , HARDY, Jean-Claude , MIGNANI, Serge
发明人： RHONE-POULENC RORER S.A.
IPC分类号： C07D487/04
CPC分类号： C07D487/04 , C07F9/6561
摘要： Compounds of formula (I), wherein R is a -CO-CH2-PO3H2, -CO-NH-tetrazole-5-yl, -CO-NHOH, -CO-NH-NH2, -alk-COOH, -alk-COOalk', -CH2-PO3H2, -CO-NH-SO2-R1 or -CH=CH-COOH radical, or a phenyl radical substituted by a carboxy radical, alk and alk' are an alkyl radical and R1 is an alkyl, trifluoromethyl or phenyl radical optionally substituted by a carboxy or alkoxycarbonyl radical, racemic mixtures, isomers, enantiomers and diastereoisomers thereof, salts thereof, the preparation thereof and drugs containing said compounds, are disclosed.
摘要翻译：式（I）化合物，其中R是-CO-CH 2 -PO 3 H 2，-CO-NH-四唑-5-基，-CO-NHOH，-CO-NH-NH 2，-alk-COOH，-alk COO 或者被羧基取代的苯基，烷基和烷基是烷基，R 1是烷基，三氟甲基或三氟甲基，公开了任选被羧基或烷氧基羰基取代的苯基，其外消旋混合物，异构体，对映体和非对映异构体，其盐，其制备物和含有所述化合物的药物。

7. 发明申请

WO1997023472A1 NOVEL TAXOIDS, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME 审中-公开
标题翻译：新型紫杉醇，其制备方法及含有其的药物组合物
公开(公告)号：WO1997023472A1
公开(公告)日：1997-07-03
申请号：PCT/FR1996002030
申请日：1996-12-19
申请人： RHONE-POULENC RORER S.A. , BOUCHARD, Hervé , COMMERÇON, Alain
发明人： RHONE-POULENC RORER S.A.
IPC分类号： C07D305/14
CPC分类号： C07D305/14
摘要： Novel taxoids of general formula (I), the preparation thereof and pharmaceutical compositions containing same, are disclosed. In general formula (I), Z is a hydrogen atom or a radical of general formula (II), wherein R1 is an optionally substituted benzoyl, furoyl or thenoyl radical or a radical R2-O-CO- where R2 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, optionally substituted phenyl or heterocyclyl radical; R3 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, phenyl, naphthyl or aromatic heterocyclic radical; and R4 is a hydrogen atom or a hydroxy radical or an alkoxy, alkenyloxy, optionally substituted alkynyloxy, alkanoyloxy, alkenoyloxy, alkynoyloxy, cycloalkanoyloxy, aroyloxy, alkoxyacetyl, alkylthioacetyl, alkyloxycarbonyloxy radical, or a cycloalkyloxy, cycloalkenyloxy, carbamoyloxy, alkylcarbamoyloxy or dialkylcarbamoyloxy radical. The novel products of general formula (I), wherein Z is a radical of general formula (II), have remarkable antitumoral and antileukemic properties.
摘要翻译：公开了通式（I）的新型紫杉烷，其制备方法和含有其的药物组合物。在通式（I）中，Z是氢原子或通式（II）的基团，其中R 1是任选取代的苯甲酰基，糠基或过氧基或基团R 2 -O-CO-，其中R 2是烷基，烯基，炔基，环烷基，环烯基，双环烷基，任选取代的苯基或杂环基; R3是烷基，烯基，炔基，环烷基，环烯基，苯基，萘基或芳族杂环基; 烷氧基乙酰基，烷基硫代乙酰基，烷氧基羰基氧基或环烷氧基，环烯基氧基，氨基甲酰氧基，烷基氨基甲酰氧基或二烷基氨基甲酰氧基，其中R 4为氢原子或羟基或烷氧基，链烯氧基，任选取代的炔氧基，烷酰氧基，烯酰氧基，炔酰氧基，环烷酰氧基。通式（I）的新产物，其中Z为通式（II）的基团，具有显着的抗肿瘤和抗白血病性质。

8. 发明申请

WO1997022337A1 STABILISED NANOPARTICLES CAPABLE OF BEING FILTERED UNDER STERILE CONDITIONS 审中-公开
标题翻译：稳定的纳米粒子能够在无条件条件下过滤
公开(公告)号：WO1997022337A1
公开(公告)日：1997-06-26
申请号：PCT/FR1996002015
申请日：1996-12-18
申请人： RHONE-POULENC RORER S.A. , VERRECCHIA, Thierry
发明人： RHONE-POULENC RORER S.A.
IPC分类号： A61K09/51
CPC分类号： A61K9/5153 , A61K9/5192 , Y10S977/773 , Y10S977/795 , Y10S977/906 , Y10S977/907
摘要： Stabilised nanoparticles capable of being filtered under sterile conditions and including at least one hydrophobic, water-insoluble and non-water-dispersible polymer or copolymer (and optionally an active principle) emulsified in a solution of phospholipids and an oleic acid salt.
摘要翻译：能够在无菌条件下过滤并包括在磷脂和油酸盐溶液中乳化的至少一种疏水性，水不溶性和非水分散性聚合物或共聚物（和任选的活性成分）的稳定纳米颗粒。

9. 发明申请

WO1997021657A1 NOVEL INDANE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME 审中-公开
标题翻译：新型衍生物，其制备方法和含有其的药物组合物
公开(公告)号：WO1997021657A1
公开(公告)日：1997-06-19
申请号：PCT/FR1996001910
申请日：1996-12-02
申请人： RHONE-POULENC RORER S.A. , BOUCHARD, Hervé , COMMERÇON, Alain
发明人： RHONE-POULENC RORER S.A.
IPC分类号： C07C49/753
CPC分类号： C07C323/16 , C07C43/23 , C07C45/62 , C07C45/78 , C07C49/753 , C07C69/013 , C07C69/017 , C07C2602/08
摘要： Novel indane derivatives of general formula (I), the preparation thereof, and pharmaceutical compositions containing same, are disclosed. In general formula (I), R1 is ethyl or vinyl, R1a is H, R3a is H, R3b is H ( alpha or beta ), R4 is OH or alkanoyloxy, R4a is H, or R4 and R4a together form a ketone function, R5 and R5a are H, R6 is H or OH, R6a is H, R7 is optionally substituted methyl, R7a is H or R7 and R7a together form a methylene radical, R7b is H (with relative configuration beta ) and R8 is OH, alkoxy or alkanoyloxy, with the proviso that when R4 is OH and R4a is H, or R4 and R4a together form a ketone function, R7 and R7a together form a methylene radical, R7 is optionally substituted methyl and R7a is H, then R5a and R6a may together form a bond, and when R7 is optionally substituted methyl, R6 is OH and R4 is OH or alkanoyloxy, then R3b-R4a, R5a-R6a and R7a-R7b each form a bond. Said novel derivatives have remarkable antitumoral and antileleucémiques properties.
摘要翻译：公开了通式（I）的新型二氢化茚衍生物，其制备方法和含有其的药物组合物。在通式（Ⅰ）中，R1是乙基或乙烯基，R1a是H，R3a是H，R3b是H（α或β），R4是OH或烷酰氧基，R4a是H或R4和R4a一起形成酮官能团， R5和R5a是H，R6是H或OH，R6a是H，R7是任选取代的甲基，R7a是H或R7，R7a一起形成亚甲基，R7b是H（具有相对构型β），R8是OH，烷氧基或烷酰氧基，条件是当R4为OH且R4a为H时，或R4和R4a一起形成酮官能团时，R7和R7a一起形成亚甲基，R7为任选取代的甲基，R7a为H，则R5a和R6a可以一起形成键，当R 7为任选取代的甲基时，R 6为OH，R 4为OH或烷酰氧基，则R 3b，R 4a，R 5a，R 6a和R 7aa-R 7b各自形成键。所述新型衍生物具有显着的抗肿瘤和抗粘液性。

10. 发明申请

WO1997018185A1 LIPOPOLYAMINES AS TRANSFECTION AGENTS AND PHARMACEUTICAL USES THEREOF 审中-公开
标题翻译：作为转移剂及其药物用途的磷酸胺
公开(公告)号：WO1997018185A1
公开(公告)日：1997-05-22
申请号：PCT/FR1996001774
申请日：1996-11-08
申请人： RHONE-POULENC RORER S.A. , BYK, Gérardo , SCHERMAN, Daniel , SCHWARTZ, Bertrand , DUBERTRET, Catherine
发明人： RHONE-POULENC RORER S.A.
IPC分类号： C07C237/06
CPC分类号： G11B19/04 , A61K38/00 , A61K47/543 , A61K47/68 , C07C237/06 , C07C237/12 , C07D495/04 , C07H15/12 , C07J41/0055 , C07K5/06026 , G11B20/10009 , G11B20/1258 , G11B20/1816 , G11B20/1866 , G11B20/24 , G11B2020/1476 , G11B2020/183
摘要： Lipopolyamines of formula (I), wherein each of R1, R2 and R3, which are the same or different, is a hydrogen atom or a -(CH2)q-NRR' grouping, where q is independently 1, 2, 3, 4, 5 or 6 for each of the groupings R1, R2 and R3; each of m, n and p, which are the same or different, is an integer from 0 to 6; and R4 is a grouping of general formula (II), wherein each of R6 and R7, which are the same or different, is a hydrogen atom or a saturated or unsaturated C10-22 aliphatic radical, with the proviso that at least one of the two groupings is not hydrogen, u is an integer from 0 to 10, X is an oxygen or sulphur atom or an optionally monoalkylated amine grouping, Y is a carbonyl or methylene grouping, R5 is a hydrogen atom or an optionally substituted natural amino acid side chain, and r is an integer from 1 to 10, with the proviso that when r is 1, R5 is an optionally substituted natural amino acid side chain, and when r is more than 1, R5 is a hydrogen atom, are disclosed. Pharmaceutical compositions containing said lipopolyamines, and the use thereof for in vitro or in vivo nucleic acid transfection in cells, are also disclosed.
摘要翻译：式（I）的脂多胺，其中相同或不同的R1，R2和R3各自为氢原子或 - （CH2）q-NRR'基团，其中q独立地为1,2,3,4 ，每个R1，R2和R3分别为5或6; m，n和p各自相同或不同，为0〜6的整数; 并且R 4是通式（II）的基团，其中R 6和R 7各自相同或不同，为氢原子或饱和或不饱和的C 10-22脂族基，条件是至少一个两个分组不是氢，u是0至10的整数，X是氧或硫原子或任选的单烷基化胺基，Y是羰基或亚甲基，R 5是氢原子或任选取代的天然氨基酸侧链，r为1〜10的整数，条件是当r为1时，R 5为任选取代的天然氨基酸侧链，当r大于1时，R5为氢原子。还公开了含有所述脂多胺的药物组合物及其在体外或体内核酸转染细胞中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式